Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, patients with heart failure and reduced ejection fraction that are homozygous for ADRB1 Ser49 were significantly more likely to experience LVEF recovery than Gly49 carriers.
|
30756358 |
2019 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Bucindolol is a beta-blocker whose unique pharmacologic properties provide greater benefit in HF patients with reduced ejection fraction (HFrEF) who have the beta<sub>1</sub>-adrenergic receptor (ADRB1) Arg389Arg genotype.
|
31042551 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
β2-adrenergic receptor autoantibodies alleviated myocardial damage induced by β1-adrenergic receptor autoantibodies in heart failure.
|
29746700 |
2018 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
GENETIC-AF is the first randomized trial of pharmacogenetic guided rhythm control, and will test the safety and efficacy of bucindolol compared with metoprolol succinate for the prevention of recurrent symptomatic AF/AFL in patients with HFrEF and an ADRB1 Arg389Arg genotype.(ClinicalTrials.govNCT01970501).
|
29754666 |
2018 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Results Subjects in each trial had less all-cause mortality with high- versus no/low-dose BB if they had ADRB1 Arg389Arg (BEST: hazard ratio [HR]=0.40, P=0.002; HF-ACTION: HR=0.45, P=0.005) but not Arg389Gly genotype (both P>0.2).
|
30354340 |
2018 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of β1-AR was significantly decreased in the left ventricle tissue of HF rats by immunohistochemistry and immunofluorescence.
|
29247373 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The lack of cardiac β1-adrenergic receptors (β1-AR) negatively affects the regulation of both cardiac inotropy and lusitropy, leading, in the long term, to heart failure (HF).
|
29466489 |
2018 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Let-7a regulates β1-AR expression and forms a negative feedback loop with β1-AR signaling pathway in ischemic heart failure.
|
28060734 |
2017 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
More consistent to mammalians, adult zebrafish developed significant heart failure in concert with β1-AR downregulation, and GRK2 and brain natriuretic peptide (BNP) upregulation in response to prolonged, 14d ISO-stimulation.
|
28554511 |
2017 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Data from our study suggest that the β adrenoreceptor Gly 49 allele of the β1 -adrenergic receptor Ser(49) Gly polymorphisms may increase the risk of ICD shock in patients with heart failure, independent of beta-blocker dosage.
|
27027728 |
2016 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
|
26879662 |
2016 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings that BAG3 is localized at the sarcolemma and t-tubules while modulating myocyte contraction and action potential duration through specific interaction with the β1-adrenergic receptor and L-type Ca(2+) channel provide novel insight into the role of BAG3 in cardiomyopathies and increased arrhythmia risks in heart failure.
|
26796036 |
2016 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the β1 adrenergic receptor gene Arg389Gly polymorphism might not be associated with heart failure risk.
|
26125791 |
2015 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.
|
23969695 |
2013 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The present study sought to investigate whether ADRB1 Arg389Gly (rs1801253), GNAS -1211 G/A (rs6123837) and GNAS 2291 C/T (rs6026584) variants are associated with left ventricular function and exercise tolerance in heart failure patients.
|
23065660 |
2013 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Detection of anti-β1-AR autoantibodies in heart failure by a cell-based competition ELISA.
|
22811559 |
2012 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The common polymorphisms producing changes in the β(1)-ARs, and their signaling pathways, have been associated with clinical outcomes in several studies in hypertension and heart failure.
|
22621216 |
2012 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This pharmacogenetic substudy of the prospective, double-blind, randomized CIBIS-ELD trial determined the impact of the β1-adrenoceptor Arg189Gly polymorphism on heart-rate responses to bisoprolol or carvedilol in elderly patients with heart failure (421 with sinus rhythm, 107 with atrial fibrillation).
|
22617224 |
2012 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of β(1)- adrenergic receptors (β(1)-ARs) and increased expression/function of G-protein-coupled receptor kinase 2 (GRK2) have been observed in human heart failure, but changes in expression of other ARs and GRKs have not been established.
|
22685168 |
2012 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thus, we performed a meta-analysis of studies to evaluate the impact of β1-AR polymorphisms on susceptibility to HF, the response to β-blocker therapy and the prognosis of HF.
|
22815685 |
2012 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The authors' laboratory has thus pursued genetic variation of the beta(1)-AR gene at the molecular, cellular, physiologic, and clinical levels as the potential basis for interindividual variability in the response to beta-blocker treatment during heart failure.
|
19945058 |
2010 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The purpose of the present study was to determine whether specific genetic polymorphisms in ADRB1 (encoding the beta1-adrenergic receptor), CYP2D6, and UGT1A1 correlated with dose of, or response to, metoprolol or carvedilol treatment in patients with heart failure.
|
20643254 |
2010 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A total of 226 patients with end-stage HF (ejection fraction ≤35%) were genotyped for the two β(1)AR SNPs and the three β(2)AR SNPs.
|
20803192 |
2010 |
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
During long-term carvedilol therapy, CHF patients with the Arg/Arg genotype of the ADRB1 gene were observed to have a more pronounced decrease in the functional class of heart failure, a significant increase in left ventricular ejection, and a decrease in left ventricular end-systolic and end-diastolic sizes as compared with patients with the Gly/Arg genotype.
|
21516734 |
2010 |
Heart failure
|
0.600 |
Biomarker
|
disease |
RGD |
Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor.
|
19587314 |
2009 |